Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced stage,
with systemic therapy being the mainstay of treatment. Survival continues to be limited …

Pancreatic ductal adenocarcinoma is the seventh leading cause of cancer death worldwide
with an estimated 432 242 deaths occurring in 2018. This estimate, in conjunction with the …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death
worldwide. PDAC is an aggressive disease with an 11-month median overall survival and a …

Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy with an overall 5-year
survival of 8% for all stages combined. The majority of patients present with stage IV disease …

Pancreatic ductal adenocarcinoma (PDAC) has a rising incidence and is one of the most
lethal human malignancies. Much is known regarding the biology and pathophysiology of …

Introduction: Prognosis remains dismal for pancreatic ductal adenocarcinoma (PDAC).
Genomics and proteomics have depicted heterogeneity in PDAC. Collectively, this …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal human cancers due to its
complicated genomic instability. PDAC frequently presents at an advanced stage with …

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …